Related Articles
Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma (Review)
Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma
Sorafenib with doxorubicin augments cytotoxicity to renal cell cancer through PERK inhibition
Polyphenols in cancer prevention: New insights (Review)
Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)